Although ERG activation mediated oncogenic processes may be bypassed in advanced prostate cancer, hormone-regulated expression of ERG has been described to persist also in castration resistant prostate cancer, supporting the importance of this rearrangement also in advanced disease [15], [20], [21]. The gene discussed is ERG; the disease is Familial prostate cancer.